R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings
Executive Summary
Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said
You may also be interested in...
“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says
"Project BioShield" offers a model that policymakers should consider to encourage research in infectious diseases, FDA Commissioner McClellan told the Commonwealth Club in San Francisco June 9
Drug R&D For Global Diseases Needs Revenue Incentives – BIO Meeting
Development of vaccines for diseases prevalent in the developing world would be most effectively promoted by revenue-enhancing incentives, speakers at a Biotechnology Industry Association/Bill & Melinda Gates Foundation forum said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011